Results 151 to 160 of about 20,268 (224)

Effect of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. [PDF]

J Cardiovasc Dev Dis
Behers BJ, Sanchez C, Hozayen O, Hozayen Y, Kammer R, Corrigan WT, Stephenson-Moe CA, Miller MW, Idriss M, Cekan LE, King AD, Brown GH, Hamad KM.   +12 more
europepmc   +1 more source

Glycative Stress Disrupts the Mitochondrial‐Lysosome Axis and Promotes Geroconversion in Aging Cardiomyocytes

Aging Cell, Volume 25, Issue 3, March 2026.
Cardiac aging promotes mitochondrial AGE accumulation driven by defective glycative stress detoxification. AGE‐modified mitochondria disrupt lysosomal proteolysis, impairing mitophagy and promoting lipofuscin buildup. This mechanism sustains chronic unresolved mitochondrial damage, driving proinflammatory senescence in cardiomyocytes and defining a ...
Diana Bou‐Teen, Simonas Valiuska, Elisabet Miro‐Casas, Chiara Rubeo, Elena Bonzon‐Kulichenko, Zuzana Nichtova, Celia Fernandez‐Sanz, Javier Inserte, Antonio Rodriguez‐Sinovas, Begoña Benito, Eduard Ródenas‐Alesina, Jesús Vázquez, Ignacio Ferreira‐González, Marisol Ruiz‐Meana   +13 more
wiley   +1 more source

Preserved Ejection, Lost Rhythm: A Narrative Review of the Pathophysiology and Management of Heart Failure with Preserved Ejection Fraction and Concomitant Atrial Fibrillation. [PDF]

J Clin Med
Ballatore A, Poggio A, Sullivan AP, Saglietto A, De Ferrari GM, Anselmino M.   +5 more
europepmc   +1 more source

Deep learning‐enhanced 3D imaging unveils semaglutide impact on cardiac fibrosis

British Journal of Pharmacology, Volume 183, Issue 5, Page 1030-1047, March 2026.
Background and Purpose Myocardial fibrosis (MF), a hallmark of structural cardiac remodelling, drives disease progression across most forms of heart failure and plays a central role in heart failure with preserved ejection fraction (HFpEF). Despite its clinical relevance, effective treatments remain scarce.
Sheyla Barrado‐Ballestero, Sarah Torp Yttergren, Max Hahn, Marie Biviano Rosenkilde, Ditte Marie Jensen, Michael Christensen, Louise Thisted, Heidi Lindgreen Holmberg, Geoffrey Teixeira, Tor Biering‐Sørensen, Casper Gravesen Salinas, Urmas Roostalu   +11 more
wiley   +1 more source

The Role of Glucagon-like Peptide-1 in the Pathophysiology of Heart Failure: A Special Focus. [PDF]

Card Fail Rev
Rakisheva A, Zatsarinnyy A.
europepmc   +1 more source

Prognostic models for all‐cause and cardiovascular mortality in type 2 diabetes: Systematic review

Diabetic Medicine, Volume 43, Issue 3, March 2026.
Abstract Aims The elevated risk of all‐cause and cardiovascular mortality in individuals with type 2 diabetes mellitus (T2DM) has led to growing efforts to develop prognostic models for early identification of high‐risk individuals. This systematic review synthesised existing models to inform future model development, enhance predictive performance and
Monica Kundu, Mark P. Funnell, Zahra Karimi, Setor K. Kunutsor, Sara Naderpour, Arron Peace, Anneka Welford, Francesco Zaccardi, Kamlesh Khunti, Safoora Gharibzadeh, Ash Routen   +10 more
wiley   +1 more source

Cellular Interactions and Immunometabolic Mechanisms in Heart Failure With Preserved Ejection Fraction: From Molecular Mechanisms to Clinical Evidence. [PDF]

Circ Heart Fail
Peikert A, Vacca A, Norata GD, Schiattarella GG, Osto E.   +4 more
europepmc   +1 more source

Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER)

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 2403-2415, March 2026.
Abstract Aims To assess the real‐world effectiveness of semaglutide versus tirzepatide in reducing major adverse cardiovascular events (MACE) among patients with overweight/obesity and established atherosclerotic cardiovascular disease (ASCVD) without diabetes in an insured US population.
Lauren Wilson, Zhenxiang Zhao, Victoria Divino, Matthew Bassan, Bríain Ó. Hartaigh, Signe Stensen, Kerem Ozer   +6 more
wiley   +1 more source

Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension. [PDF]

Circulation
Reddy YNV, Frantz RP, Miranda WR, Asokan AK, Varma R, Rischard F, Hassoun PM, Hemnes AR, Horn E, Leopold JA, Rosenzweig EB, Hill NS, Erzurum SC, Beck GJ, Barnard J, Finet JE, Kwon D, Mathai SC, Mukherjee M, Tang WHW, Nair KS, Borlaug BA.   +21 more
europepmc   +1 more source

Phenotyping of acute heart failure with preserved ejection fraction: real‐world outcomes in a cohort of older patients

Internal Medicine Journal, Volume 56, Issue 3, Page 373-382, March 2026.
Abstract Background Previous studies have identified distinct subgroups (phenogroups) of patients with heart failure with preserved ejection fraction (HFpEF). Aims This study aims to identify distinct phenotypes in older patients with HFpEF hospitalised for acute heart failure (AHF) and investigate the relationship between subgroups and outcomes ...
Maria Livia Burzo *, Giuseppe De Matteis, Amato Serra, Davide Antonio Della Polla, Mariella Fuorlo, Maria Anna Nicolazzi, Benedetta Simeoni, Antonio Gasbarrini, Francesco Franceschi, Giovanni Gambassi, Marcello Covino   +10 more
wiley   +1 more source